Immune response in hepatitis B virus infection

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 8, 2015, Pages 1-18

  Tan, Anthony ^a   Koh, Sarene ^b   Bertoletti, Antonio ^a,b,c  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; ARTICLE; CYTOKINE PRODUCTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; LIVER INJURY; NATURAL KILLER CELL; NATURAL KILLER T CELL; REGULATORY T LYMPHOCYTE; TH22 CELL; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS REPLICATION; CELLULAR IMMUNITY; FEMALE; IMMUNOLOGY; MALE; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VIROLOGY;

HEPATITIS B VIRUS;

ADAPTIVE IMMUNITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; MALE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84938679974     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a021428     Document Type: Article

References (155)

1. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124: 783–801.
2. Alberti A, Diana S, Sculard GH, Eddleston AL, Williams R. 1978. Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J 2: 1056–1058.
3. Anand S, Wang P, Yoshimura K, Choi I, Hilliard A, Chen YH, Wang C, Schulick R, Flies AS, Flies DB, et al. 2006. Essential role of TNF family molecule LIGHTas a cytokine in the pathogenesis of hepatitis. J Clin Invest 116: 1045– 1051.
4. Andrade BB, Santos CJN, Camargo LM, Souza-Neto SM, Reis-Filho A, Clarêncio J, Mendonça VRR, Luz NF, Camargo EP, Barral A, et al. 2011. Hepatitis B infection is associated with asymptomatic malaria in the Brazilian Amazon. PLoS ONE 6: e19841.
5. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen Y-B. 2013. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. J Clin Oncol 31: 4199–4206.
6. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH, Chisari FV. 2009. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 83: 9652–9662.
7. Beckebaum S, Cicinnati VR, Zhang X, Ferencik S, Frilling A, Grosse-Wilde H, Broelsch CE, Gerken G. 2003. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: Mechanisms for viral immune escape. Immunology 109: 487–495.
8. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M. 2012. IFN-a inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 122: 529–537.
9. Bertoletti A, Ferrari C. 2003. Kinetics of the immune response during HBV and HCV infection. Hepatology 38: 4–13.
10. Bertoletti A, Kennedy PT. 2014. The immune tolerant phase of chronic HBV infection: New perspectives on an old concept. Cell Mol Immunol doi: 10.1038/cmi.2014.79.
11. Bertoletti A, Maini MK, Ferrari C. 2010. The host–pathogen interaction during HBV infection: Immunological controversies. Antivir Ther 15: 15–24.
12. + T cells within the liver. J Immunol 166: 5430–5438.
13. + T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci 107: 3006–3011.
14. Biron CA, Brossay L. 2001. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 13: 458–464.
15. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, et al. 2003. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39: 595–605.
16. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, et al. 2007. Characterization of hepatitis B virus (HBV)specific T-cell dysfunction in chronic HBV infection. J Virol 81: 4215–4225.
17. Boni C, Laccabue D, Lampertico P, Giuberti T, Viganò M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, et al. 2012. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143: 963–973.
18. Cavanaugh VJ, Guidotti LG, Chisari FV. 1998. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol 72: 2630–2637.
19. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA. 1999. An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 104: 777–785.
20. Chisari FV. 1978. Regulation of human lymphocyte function by a soluble extract from normal human liver. J Immunol 121: 1279–1286.
21. Chisari FV. 1997. Cytotoxic T cells and viral hepatitis. J Clin Invest 1472–1477.
22. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH. 2007. Inhibition of a interferon signaling by hepatitis B virus. J Virol 81: 159–165.
23. Coffin CS, Michalak TI. 1999. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. J Clin Invest 104: 203–212.
24. Couillin I, Pol S, Mancini M, Driss F, Bréchot C, Tiollais P, Michel ML. 1999. Specific vaccine therapy in chronic hepatitis B: Induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180: 15–26.
25. Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP. 2000. The liver as a site of T-cell apoptosis: Graveyard, or killing field? Immunol Rev 174: 47–62.
26. Dandri M, Burda MR, Török E, Pollok JM, Iwanska A, Sommer G, Rogiers X, Rogler CE, Gupta S, Will H, et al. 2001. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33: 981–988.
27. Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PTF, Alexander G, Finney H, Lawson A, Plunkett FJ, et al. 2008. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 205: 2111–2124.
28. Das A, Ellis G, Pallant C, Lopes AR, Khanna P, Peppa D, Chen A, Blair P, Dusheiko G, Gill U, et al. 2012. IL10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. J Immunol 189: 3925–3935.
29. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, et al. 2007. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204: 667–680.
30. Dunn C, Peppa D, Khanna P, Nebbia G, Jones M, Brendish N, Lascar RM, Brown D, Gilson RJ, Tedder RJ, et al. 2009. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137: 1289–1300.
31. Durantel D, Zoulim F. 2009. Innate response to hepatitis B virus infection: Observations challenging the concept of a stealth virus. Hepatology 50: 1692–1695.
32. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C. 2009. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58: 974–982.
33. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini EM, Andreone P, Missale G, et al. 2010. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138: 682–693.
34. Fisicaro P, Valdatta C, Massari M, Loggi E, Ravanetti L, Urbani S, Giuberti T, Cavalli A, Vandelli C, Andreone P, et al. 2012. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 143: 1576–1585.
35. Fletcher SP, Chin DJ, Ji Y, Iniguez AL, Taillon B, Swinney DC, Ravindran P, Cheng DT, Bitter H, Lopatin U, et al. 2012. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology 56: 820–830.
36. Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, Stark GR. 1991. Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons a and g and double-stranded RNA. Proc Natl Acad Sci 88: 2888–2892.
37. + regulatory T cells in patients with hepatitis B virus infection. J Virol 79: 3322–3328.
38. Gehring AJ, Koh S, Chia A, Paramasivam K, Chew VS, Ho ZZ, Lee KH, Maini MK, Madhavan K, Lim SG, et al. 2011a. Licensing virus-specific T cells to secrete the neutrophil attracting chemokine CXCL-8 during hepatitis B virus infection. PLoS ONE 6: e23330.
39. Gehring AJ, Xue S-A, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, et al. 2011b. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 55: 103–110.
40. Gehring AJ, Haniffa M, Kennedy PT, Ho ZZ, Boni C, Shin A, Banu N, Chia A, Lim SG, Ferrari C, et al. 2013. Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest 123: 3766–3776.
41. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, Ye K, Vannier E, Wolff SM, Dinarello CA. 1993. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 151: 1637–1645.
42. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. 2002. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci 99: 15655–15660.
43. Guidotti LG. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284: 825–829.
44. Guidotti LG, Chisari FV. 2006. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1: 23–61.
45. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4: 25– 36.
46. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A, Block TM, Guo J-T. 2009. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 83: 847–858.
47. Guy CS, Mulrooney-Cousins PM, Churchill ND, Michalak TI. 2008. Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus. J Virol 82: 8579–8591.
48. Hantz O, Parent R, Durantel D, Gripon P, Guguen-Guillouzo C, Zoulim F. 2009. Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells. J Gen Virol 90: 127–135.
49. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien P-A, et al. 2009. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16: 295–308.
50. Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, et al. 2009. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50: 1773–1782.
51. + T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol 14: 574–583.
52. Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, Chisari FV, Ruggeri ZM, Guidotti LG. 2005. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 11: 1167–1169.
53. Iannacone M, Sitia G, Ruggeri ZM, Guidotti LG. 2007. HBV pathogenesis in animal models: Recent advances on the role of platelets. J Hepatol 46: 719–726.
54. Isogawa M, Robek MD, Furuichi Y, Chisari FV. 2005. Tolllike receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79: 7269–7272.
55. + T cells from PD1-mediated exhaustion. PLoS Pathog 9: e1003490.
56. Ji C, Sastry KSR, Tiefenthaler G, Cano J, Tang T, Ho ZZ, Teoh D, Bohini S, Chen A, Sankuratri S, et al. 2012. Targeted delivery of interferon-a to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology 56: 2027–2038.
57. Jo J, Tan AT, Bertoletti A. 2013. Murine models and human studies of pathogenesis of chronic hepatitis B. In Viral hepatitis, 4th ed. (ed. Thomas HC, Lok ASF, Locarnini SA, Zuckerman AJ), pp. 176–187. Wiley, Oxford.
58. Jo J, Tan AT, Ussher JE, Sandalova E, Tang X-Z, Tan-Garcia A, To N, Hong M, Chia A, Gill US, et al. 2014. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog 10: e1004210.
59. Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR, Bertoletti A. 2012. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 143: 637–645.
60. Kim K-A, Lin W, Tai AW, Shao R-X, Weinberg E, De Sa Borges CB, Bhan AK, Zheng H, Kamegaya Y, Chung RT. 2009. Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection. J Hepatol 50: 705–711.
61. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. 2002. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 76: 10702–10707.
62. Koeberlein B, zur Hausen A, Bektas N, Zentgraf H, Chin R, Nguyen LT, Kandolf R, Torresi J, Bock C-T. 2010. Hepatitis B virus overexpresses suppressor of cytokine signaling-3 (SOCS3) thereby contributing to severity of inflammation in the liver. Virus Res 148: 51–59.
63. Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, et al. 2013. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids 2: e114.
64. Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, et al. 2013. Combination of DNA prime—Adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 9: e1003391.
65. Krebs K, Böttinger N, Huang L-R, Chmielewski M, Arzberger S, Gasteiger G, Jäger C, Schmitt E, Bohne F, Aichler M, et al. 2013. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145: 456–465.
66. Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL. 2011. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of b interferon. J Virol 85: 987–995.
67. Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, Fosdick A, Frey CR, Zheng J, Wolfgang G, et al. 2013. GS-9620, an oral agonist of Toll-like receptor7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144: 1508–1517.
68. Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, Möller I, Seiz P, Glebe D, Wang B, et al. 2014. Enhancing virusspecific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 10: e1003856.
69. Loggi E, Bihl F, Chisholm JV, Biselli M, Bontadini A, Vitale G, Ercolani G, Grazi GL, Pinna AD, Bernardi M, et al. 2009. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving an HBsAg positive graft. J Hepatol 50: 625–630.
70. + T cells in patients unable to control HBV infection. J Clin Invest 118: 1835–1845.
71. Lucifora J, Durantel D, Testoni B, Hantz O, Levrero M, Zoulim F. 2010. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51: 63–72.
72. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, et al. 2014. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343: 1221–1228.
73. Lütgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann J-H, Pollok JM, Lohse AW, Petersen J, Dandri M. 2011. Hepatitis B virus limits response of human hepatocytes to interferon-a in chimeric mice. Gastroenterology 140: 2074–2083.
74. Maini MK, Schurich A. 2010. The molecular basis of the failed immune response in chronic HBV: Therapeutic implications. J Hepatol 52: 616–619.
75. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191: 1269–1280.
76. + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191: 1269–1280.
77. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Bréchot C, Michel M-L. 2004. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40: 874–882.
78. Mancini-Bourgine M, Fontaine H, Bréchot C, Pol S, Michel M-L. 2006. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24: 4482–4489.
79. Marshall HD, Urban SL, Welsh RM. 2011. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J Virol 85: 5929– 5939.
80. Martinet J, Dufeu-Duchesne T, Bruder Costa J, Larrat S, Marlu A, Leroy V, Plumas J, Aspord C. 2012. Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 143: 1586– 1596.
81. Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, Netto-Cardoso ACF, Lada O, Batrla R, Krause F, Asselah T, Marcellin P. 2013. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. J Hepatol 58: 1089–1095.
82. Menne S, Tennant BC, Liu KH, Ascenzi MA, Baldwin BH, Bellezza CA, Cote PJ, Zheng X, Wolfgang G, Turnas D. 2011. Anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. J Hepatol 54: S441.
83. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, et al. 2013. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-a therapy of chronic hepatitis B. J Hepatol 58: 225–233.
84. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. 1994. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 94: 230–239.
85. Mueller SN, Ahmed R. 2009. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci 106: 8623–8628.
86. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. 1998. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 188: 341–350.
87. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon therapy. Science 282: 103–107.
88. Oakley MS, Sahu BR, Lotspeich-Cole L, Solanki NR, Majam V, Pham PT, Banerjee R, Kozakai Y, Derrick SC, Kumar S, et al. 2013. The transcription factor T-bet regulates parasitemia and promotes pathogenesis during Plasmodium berghei ANKA murine malaria. J Immunol 191: 4699– 4708.
89. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, De Filippi F, Bruno S, Mondelli MU. 2009. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 137: 1151–1160.
90. Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG, Woltman AM. 2009. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: A possible immune escape mechanism of hepatitis B virus. Immunology 126: 280–289.
91. + T cells. Science 327: 1098–1102.
92. Peppa D, Micco L, Javaid A, Kennedy PTF, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, et al. 2010. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 6: e1001227.
93. Peppa D, Gill US, Reynolds G, Easom NJW, Pallett LJ, Schurich A, Micco L, Nebbia G, Singh HD, Adams DH, et al. 2013. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 210: 99–114.
94. Petersen J, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok J-M, Erbes B, et al. 2008. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26: 335–341.
95. + T cell control of hepatitis B virus replication: Direct comparison between cytolytic and noncytolytic functions. J Immunol 184: 287–295.
96. Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, Brécho C. 2001. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34: 917–921.
97. Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, Van Rooijen N, Wakil AE, Peters M, et al. 2013. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest 123: 3728–3739.
98. + T-cell function. Hepatology 52: 1934–1947.
99. Rehermann B. 1996. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2: 1104–1108.
100. Rehermann B, Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215–229.
101. Rodrick ML, Moss NM, Grbic JT, Revhaug A, O’Dwyer ST, Michie HR, Gough DB, Dubravec D, Manson JM, Saporoschetz IB, et al. 1992. Effects of in vivo endotoxin infusions on in vitro cellular immune responses in humans. J Clin Immunol 12: 440–450.
102. Roggendorf M, Tolle TK. 1995. The woodchuck: An animal model for hepatitis B virus infection in man. Intervirology 38: 100–112.
103. Sallberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend KAY, Anderson C, Dea JO, Alfonso J, Eason R, et al. 1998. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 9: 1719–1729.
104. Sandalova E, Laccabue D, Boni C, Tan AT, Fink K, Ooi EE, Chua R, Shafaeddin Schreve B, Ferrari C, Bertoletti A. 2010. Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PLoS Pathog 6: e1001051.
105. Sandalova E, Laccabue D, Boni C, Watanabe T, Tan A, Zong HZ, Ferrari C, Bertoletti A. 2012. Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology 143: 78–87.
106. Sastry KSR, Too CT, Kaur K, Gehring AJ, Low L, Javiad A, Pollicino T, Li L, Kennedy PTF, Lopatin U, et al. 2011. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol 85: 1935–1942.
107. Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, Nebbia G, Kennedy PTF, Geretti A-M, Dusheiko G, et al. 2011. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53: 1494–1503.
108. Seeger C, Mason WS. 2000. Hepatitis B virus biology. Microbiol Mol Biol Rev 64: 51–68.
109. Seto W-K, Wong DK, Fung J, Ip PPC, Yuen JC, Hung IF, Lai CL, Yuen MF. 2012. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS ONE 7: e43087.
110. Sharma S, Fitzgerald KA. 2011. Innate immune sensing of DNA. PLoS Pathog 7: e1001310.
111. Shi B, Ren G, Hu Y, Wang S, Zhang Z, Yuan Z. 2012. HBsAg inhibits IFN-a production in plasmacytoid dendritic cells through TNF-a and IL-10 induction in monocytes. PLoS ONE 7: e44900.
112. Sitia G, Isogawa M, Kakimi K, Wieland SF, Chisari FV, Guidotti LG. 2002. Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. Proc Natl Acad Sci 99: 13717–13722.
113. Sitia G, Isogawa M, Iannacone M, Campbell IL, Chisari FV, Guidotti LG. 2004. MMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLs. J Clin Invest 113: 1158–1167.
114. Sitia G, Iannacone M, Müller S, Bianchi ME, Guidotti LG. 2007. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 81: 100–107.
115. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, Esposito A, Ruggeri ZM, Chisari FV, Iannacone M, et al. 2012. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci 109: E2165–E2172.
116. Stabenow D, Frings M, Trück C, Gärtner K, Förster I, Kurts C, Tüting T, Odenthal M, Dienes H-P, Cederbrant K, et al. 2010. Bioluminescence imaging allows measuring CD8 T cell function in the liver. Hepatology 51: 1430–1437.
117. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, et al. 2009. Induction of a striking systemic cytokine cascade before peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 83: 3719–3733.
118. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL. 2005. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41: 771–778.
119. Sudhamsu J, Yin J, Chiang EY, Starovasnik MA, Grogan JL, Hymowitz SG. 2013. Dimerization of LTbRbyLTa1b2is necessary and sufficient for signal transduction. Proc Natl Acad Sci 110: 19896–19901.
120. Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, Wei H. 2012. TGF-b1 down-regulation of NKG2D/DAP10 and 2B4/ SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog 8: e1002594.
121. Tan AT, Hoang LT, Chin D, Rasmussen E, Lopatin U, Hart S, Bitter H, Chu T, Gruenbaum L, Ravindran P, et al. 2014. Reduction of HBV replication prolongs the early immunological response to IFNa therapy. J Hepatol 60: 54–61.
122. Tang X-Z, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, Lee KH, Gehring AJ, De Libero G, Bertoletti A. 2013. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol 190: 3142–3152.
123. Tian Y, Chen W, Ou JJ. 2011. Effects of interferon-a/b on HBV replication determined by viral load. PLoS Pathog 7: e1002159.
124. Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN, Orloff MS. 2008. TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med 205: 233–244.
125. Unterholzner L, Bowie AG. 2011. Innate DNA sensing moves to the nucleus. Cell Host Microbe 9: 351–353.
126. + IL-18 in a TCR-independent manner. Eur J Immunol 44: 195–203.
127. Van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HGM, Kusters JG, Kwekkeboom J, Janssen HLA. 2004. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40: 738–746.
128. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, Rodgers S, Kurtovic J, Chang J, Lewin S, et al. 2007. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 45: 102–110.
129. Wang H, Ryu W-S. 2010. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: Implications for immune evasion. PLoS Pathog 6: e1000986.
130. Wang X, Li Y, Mao A, Li C, Li Y, Tien P. 2010. Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-b induction by disrupting the VISA-associated complex. Cell Mol Immunol 7: 341–348.
131. Wang Q, Zhou J, Zhang B, Tian Z, Tang J, Zheng Y, Huang Z, Tian Y, Jia Z, Tang Y, et al. 2013. Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis. PLoS Pathog 9: e1003410.
132. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, Brown D, Amlot PL, Williams R, Vergani D, et al. 2000. Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 32: 1117– 1124.
133. + T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: Implications for immunotherapy. J Virol 78: 5707–5719.
134. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, et al. 2010. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 185: 1158– 1168.
135. Wherry EJ, Ahmed R. 2004. Memory CD8 T-cell differentiation during viral infection. J Virol 78: 5535–5545.
136. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. 2004. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci 101: 16004–16009.
137. Wherry EJ, Blattman JN, Ahmed R. 2005. Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. J Virol 79: 8960– 8968.
138. Wieland SF, Chisari FV. 2005. Stealth and cunning: Hepatitis B and hepatitis C viruses. J Virol 79: 9369–9380.
139. Wieland S, Thimme R, Purcell RH, Chisari FV. 2004. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci 101: 6669–6674.
140. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. 2011. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE 6: e15324.
141. Wu M, Xu Y, Lin S, Zhang X, Xiang L, Yuan Z. 2007. Hepatitis B virus polymerase inhibits the interferon-inducible MyD88 promoter by blocking nuclear translocation of Stat1. J Gen Virol 88: 3260–3269.
142. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Schlaak J. 2009. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49: 1132–1140.
143. + regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177: 739–747.
144. Xu Y, Hu Y, Shi B, Zhang X, Wang J, Zhang Z, Shen F, Zhang Q, Sun S, Yuan Z. 2009. HBsAg inhibits TLR9-mediated activation and IFN-a production in plasmacytoid dendritic cells. Mol Immunol 46: 2640–2646.
145. Xu C, Guo H, Pan X-B, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo J-T. 2010. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 84: 9332–9340.
146. Xu D-Z, Wang X-Y, Shen X-L, Gong G-Z, Ren H, Guo L-M, Sun A-M, Xu M, Li L-J, Guo X-H, et al. 2013. Results of a phase III clinical trial with an HBsAg–HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: Experiences and findings. J Hepatol 59: 450– 456.
147. Yalcin K, Acar M, Degertekin H. 2003. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: A randomized controlled trial. Infection 31: 221–225.
148. + regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int Immunol 19: 133–140.
149. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z. 2010. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated b interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKK1 and DDX3. J Gen Virol 91: 2080– 2090.
150. Zeissig S, Murata K, Sweet L, Publicover J, Hu Z, Kaser A, Bosse E, Iqbal J, Hussain MM, Balschun K, et al. 2012. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat Med 18: 1060–1068.
151. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. 2007. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27: 647–659.
152. + T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51: 81–91.
153. Zhang Y, Cobleigh Ma, Lian J-Q, Huang C-X, Booth CJ, Bai X-F, Robek MD. 2011a. A proinflammatory role for in terleukin-22 in the immune response to hepatitis B virus. Gastroenterology 141: 1897–1906.
154. Zhang Z, Zhang S, Zou Z, Shi J, Zhao J, Fan R, Qin E, Li B, Li Z, Xu X, et al. 2011b. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 53: 73–85.
155. Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, Tacke F. 2011. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS ONE 6: e21381.